Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial

Lenacapavir, a first-in-class HIV-1 capsid inhibitor, is in development as a long-acting agent for treating and preventing HIV-1. We aimed to evaluate the efficacy and safety of lenacapavir with an optimised background regimen in adults living with multidrug-resistant HIV-1 up to 52 weeks. This ongo...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The lancet HIV 2023-08, Vol.10 (8), p.e497-e505
Hauptverfasser:	Ogbuagu, Onyema, Segal-Maurer, Sorana, Ratanasuwan, Winai, Avihingsanon, Anchalee, Brinson, Cynthia, Workowski, Kimberly, Antinori, Andrea, Yazdanpanah, Yazdan, Trottier, Benoit, Wang, Hui, Margot, Nicolas, Dvory-Sobol, Hadas, Rhee, Martin S, Baeten, Jared M, Molina, Jean-Michel, DeJesus, Edwin, Richmond, Gary J., Berhe, Mezgebe, Ruane, Peter J., Sinclair, Gary Ian, Lichtenstein, Kenneth, Ramgopal, Moti N., Wiznia, Andrew, Sanchez, William, McGowan, Joseph P., Creticos, Catherine M., Berger, Daniel S., Wheeler, David A., Hagins, Debbie, Crofoot, Gordon E., Sims, James, Osiyemi, Olayemi, Hodge, Theo, Zurawski, Christine, Siripassorn, Krittaecho, Chetchotisakd, Ploenchan, Castagna, Antonella, Castelli, Francesco, Ronot-Bregigeon, Sylvie, Brunetta, Jason, Shirasaka, Takuma, Yokomaku, Yoshiyuki, Koenig, Ellen, Mallolas, Josep, Stellbrink, Hans-Jurgen, Hung, Chien-Ching, Rassool, Mohammed
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!